I generally agree with your perspectives but this sounds too much like- oh not to worry, if CTIX did not enroll adequate numbers of patients in a trial to see a difference, when in fact the filed of epidemiology exists to avoid such errors. MDPhD- what about all of those epidemiology PhD's that CTIX could employ to get it right? Should we just allow excuses for the company if they report inadequate data? I realize your post suggests that such mistakes are all part of the process, and the banker agrees with you.
I think they are a biotech firm doing clinical trials and they could be expected to do better